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Abstract
Aflatoxin B1 (AFB1) is an important carcinogen for primary hepatocellular 
carcinoma (PHCC). However, the values of blood AFB1-DNA adducts predicting 
HCC risk and prognosis have not still been clear. We conducted a hospital-based 
case-control study, consisting of 380 patients with pathologically diagnosed PHCC 
and 588 controls without any evidence of liver diseases, to elucidate the associations 
between the amount of AFB1-DNA adducts in the peripheral blood and the risk and 
outcome of HCC. All subjects had not the history of hepatitis B and C virus infec-
tion. AFB1-DNA adducts were tested using enzyme-linked immunosorbent assay. 
Cases with PHCC featured an increasing blood amount of AFB1-DNA adducts 
compared with controls (2.01 ± 0.71 vs. 0.98 ± 0.63 μmol/DNA). Increasing adduct 
amount significantly grew the risk of PHCC [risk values, 1.82 (1.34–2.48) and 3.82 
(2.71–5.40) for medium and high adduct level, respectively]. Furthermore, com-
pared with patients with low adduct level, these with medium or high adduct level 
faced a higher death and tumor-recurrence risk. These results suggest that the blood 
AFB1-DNA adducts may act as a potential biomarker for predicting the risk and 
prognosis of PHCC.
Keywords: AFB1, DNA adduct, primary hepatocellular carcinoma, biomarker, risk, 
prognosis
1. Introduction
Aflatoxin B1 (AFB1) is a knowledge I-type chemical carcinogen for primary 
hepatocellular carcinoma (PHCC) [1–3]. This carcinogen is mainly produced 
by Aspergillus parasiticus and Aspergillus flavus and often found in crops and 
food (including maize, nuts, and beans), which are raised in the areas with 
humid and hot environment [1, 4, 5]. Once these AFB1-contaminated crops 
and food are ingested by human bodies, AFB1 will be metabolized through two 
stage reactions consisting of detoxification stage (such as reduction, oxida-
tion, and hydrolytic reaction) and covalent stage (such as binding reaction and 
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conjugating reaction) [2, 3]. During the process of AFB1’s metabolism, AFB1-
DNA adducts, including AFB1-formamidopyrimidine adduct (AFB1-FAPa) and 
AFB1’s 8,9-dihydro-8-(N7-guanyl)-9-hydroxy–adduct (AFB1-GA), are frequently 
formed [2, 3]. Growing evidence has shown that AFB1-DNA adducts are usually 
tested in the tissue samples (such as liver and placenta tissues) of these individu-
als from high AFB1 exposure areas [6–10]. Recent studies have displayed that 
they are also found in the peripheral blood white cells of peoples who are from 
high AFB1 exposure areas and are associated with the time of AFB1 exposure 
[11–17]. However, the potential of blood AFB1-DNA adducts predicting PHCC 
risk and prognosis is not clear. Here, we specifically conduced a hospital-based 
case-control study to investigate whether blood AFB1-DNA adducts were related 
to the risk and outcome of PHCC.
2. Materials and methods
2.1 Study population
A total of 380 patients were recruited from the affiliated hospitals of Youjiang 
Medical University for Nationalities and Guangxi Medical University (two main 
medical universities in the AFB1-exposure areas in China) between 2011 and 2013. 
All cases were newly diagnosed as patients using histopathological method and they 
had no history of radiation or chemotherapy treatment before enrollment. A total 
of 588 controls, who were randomly recruited from a pool of healthy individuals in 
the same hospitals during the same time, were all volunteers without any evidence 
with liver diseases. To control the effects of confounder factors such as age, gender, 
and race, controls were individually matched with the cases on these factors. In 
this study, all cases and controls had no history of hepatitis B virus (HBV) and/
hepatitis C virus (HCV) infection, whereas these subjects with positive status of 
serum anti-HCV and/or hepatitis B surface antigen (HBsAg) were excluded. They 
all agreed to participate in this investigation and did not drop out. With informed 
consent, all clinicopathological data, including age, gender, race, hepatitis virus B 
and C infection information, survival follow-up information, were collected using 
healthy examination or medical records. Additionally, 10 ml of peripheral blood 
samples for all subjects were also collected for AFB1-DNA adduct analysis. In this 
study, the last following-up date was set on January 31, 2019. Overall survival (OS) 
and tumor recurrence-free survival (RFS) status were defined according to the 
previously described methods [11, 14, 18]. The study protocol was approved by the 
ethics committees of Youjiang Medical University for Nationalities and Guangxi 
Medical University.
2.2 AFB1-DNA adducts data
The amount of AFB1-DNA adducts in the peripheral blood were tested 
using the previously published methods [8, 17]. Briefly, DNA samples were first 
extracted from the peripheral blood samples and adducts were next quantitated 
by the comparative enzyme-linked immunosorbent assay (ELISA). To investigate 
the association between different levels of AFB1-DNA adducts and the risk and 
prognosis of PHCC patients, the levels of AFB1-DNA adducts were divided into 
three subgroups according to the mean adduct amounts of cases and controls: low 
AFB1-DNA adduct level (LAL, <1.00 μmol/DNA), medium AFB1-DNA adduct 
level (MAL, 1.00–2.00 μmol/DNA), and high AFB1-DNA adduct level (HAL, 
>2.00 μmol/DNA).
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2.3 Statistical analysis
All statistical analyses were accomplished with SPSS statistical package (Version 
18, SPSS Institute, Chicago, IL, USA). Test for the distribution of age, gender, and 
race between patients with PHCC and controls was accomplished using chi-square 
test. The effects of blood AFB1-DNA adducts on PHCC risk were evaluated using 
odds ratio (OR) and 95% confidence interval (CI) in the conditional logistic regres-
sion model. For survival analyses, Kaplan-Meier survival model with Log-Rank test 
and Cox regression model (the selection of significant variates based on forward-
step method with likelihood ratio test) was used to analyze the association between 
blood AFB1-DNA adducts and PHCC outcomes. Cumulative hazard value for the 
effects of adducts on the prognosis of patients with PHCC and corresponding 95% 
CI was calculated using hazard ratio (HR) from significant multivariate Cox regres-
sion model (including all significant variates). In this study, the P value <0.05 was 
defined as statistical significance.
3. Results
3.1 The features of study population
A total of 380 cases with PHCC and 588 controls were included in our final 
analyses. Baseline characteristics of all cases with PHCC and controls were summa-
rized in Table 1, and results showed there were no significant distributions of age, 
gender, and race between cases and controls.
Controls PHCCs P
n % n %
Total 588 100.0 380 100.0 —
Gender 0.70
Male 426 72.4 271 71.3
Female 162 27.6 109 28.7
Age (years) 0.78
≤35 81 13.8 53 13.9
36–40 62 10.5 38 10.0
41–45 90 15.3 55 14.5
46–50 83 14.1 43 11.3
51–55 94 16.0 56 14.7
56–60 56 9.5 42 11.1
61–65 69 11.7 49 12.9
≥66 53 9.0 44 11.6
Race 0.88
Han 339 57.7 221 58.2
Zhuang 249 42.3 159 41.8
PHCCs, patients with primary hepatocellular carcinoma.
Table 1. 
The characteristics of subjects.
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3.2 Blood AFB1-DNA adducts correlating with PHCC risk
The amount of AFB1-DNA adducts in the peripheral white blood cells were cal-
culated using ELISA technique. Compared to controls, patients with PHCC featured 
a higher level of blood AFB1-DNA adducts (0.98 ± 0.63 vs. 2.01 ± 0.71 μmol/DNA), 
suggesting blood AFB1-DNA adducts may play an important role in the PHCC 
carcinogenesis. To investigate possible correlation between AFB1-DNA adducts and 
PHCC risk, the levels of blood AFB1-DNA adducts were divided into three groups. 
Results from multivariable logistic regression analyses showed that these individu-
als with medium AFB1-DNA adduct level (MAL) had an increasing risk of PHCC 
compared to those with low AFB1-DNA adduct level (LAL) (OR = 1.82 and 95% 
CI = 1.34–2.48), whereas risk value for high AFB1-DNA adduct level (HAL) was 3.82 
(2.71–5.40) (Table 2). Altogether, these data were indicative of important potential 
risk role of blood AFB1-DNA adducts in the carcinogenesis of PHCC.
3.3 Blood AFB1-DNA adducts correlating with PHCC outcome
To explore the effects of blood AFB1-DNA adducts on the prognosis of patients 
with PHCC, we accomplished two survival model analyses. Kaplan-Meier’s 
AFB1-DNA adduct levels Controls PHCCs OR (95% CI)a P
n % n %
Low 316 53.7 122 32.1 1 —
Medium 186 31.6 131 34.5 1.82 (1.34–2.48) 1.20 × 10−4
High 86 14.6 127 33.4 3.82 (2.71–5.40) 2.35 × 10−14
aOR conditional on matched set.
AFB1, aflatoxin B1; PHCC, primary hepatocellular carcinoma.
Table 2. 
Associations between AFB1-DNA adduct levels and PHCC risk.
Figure 1. 
The aflatoxin B1 (AFB1)-DNA adducts in peripheral blood white cells significantly correlating with the 
overall survival (OS) and tumor recurrence-free survival (RFS) of primary hepatocellular carcinoma 
(PHCC). Cumulative hazard function was plotted by Kaplan-Meier’s methodology, and P value was 
calculated with two-sided log-rank tests. The relative hazard ratio (HR) values for genotypes were calculated 
using multivariable cox regression models (with all significant variables) based on forward-step method with 
likelihood ratio test. LAL, low AFB1-DNA adduct level; MAL, medium low AFB1-DNA adduct level; HAL, 
high low AFB1-DNA adduct level.
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survival analyses first tested the association between blood AFB1-DNA adducts 
and patients’ OS and results displayed that increasing level of adducts signifi-
cantly shorten the OS time of patients (P = 1.33 × 10−5) (Figure 1, left). Similar 
effects were also found in the RFS analyses (P = 2.88 × 10−7) (Figure 1, right). 
Results from multivariate Cox’s regression models further exhibited that these 
cases with an increasing level of blood AFB1-DNA adducts faced an increasing 
risk of death [HRs (95% CIs) = 1.44 (1.11–1.86) for MAL and 1.93 (1.47–2.54) for 
HAL, respectively] (Figure 1, left). For RFS, the corresponding tumor-recurrence 
risk was 1.49 (1.18–1.89) for MAL and 2.98 (1.93–4.60) for HAL, respectively 
(Figure 1, right).
4. Discussion
In this study, we explored the relationship between the blood AFB1-DNA 
adducts and the risk and prognosis of PPHCC. We found that individuals with 
an increasing level of AFB1-DNA adducts in peripheral blood white cells would 
feature higher PHCC risk (OR = 1.82 for MAL and 3.82 for HAL, respectively). 
Furthermore, the blood AFB1-DNA adduct levels were significantly associated with 
poor OS and RFS of patients with PHCC.
AFB1 acts as a major cause of PHCC in the southeast areas of China and is 
taken into human bodies through its contaminating staple foods [2]. AFB1 is 
transferred into AFB1-DNA adducts and displays its genic toxicity and hepato 
carcinogenicity [3, 19]. Mechanically, PHCC induced by AFB1 is mainly con-
cerned with DNA damage (including DNA single-/double-strand breaks, base 
damage, adduct formation, genic mutation), the dysregulation of DNA repair, 
the activation of cancer genes (such as ras and myc), the inactivation of cancer 
suppressor genes (such as TP53, BP1, H2AX, bcl2, p21, and p27), inheritance 
alterations, and/or abnormal immunoreaction [1, 20–25]. Among these knowl-
edge mechanisms and pathways, AFB1-DNA adducts and mutations at codon 
249 of TP53 gene (also termed as hot-spot mutation induced by AFB1) have 
been especially concerned in the past decades [26–29]. This is mainly because 
AFB1-DNA adducts are the key central forms in the metabolism of AFB1 in 
human bodies [19, 26, 30], whereas spot mutations at codon 249 of TP53 gene 
are highly frequent in HCC patients with AFB1 exposure [31–36]. Evidence 
from clinical epidemiology and experimental animal models has exhibited that 
they are constantly tested in biopsy samples, such as liver tissues, tumor tis-
sues, placenta tissues, and blood cells, of individuals from AFB1 exposure areas 
[6, 8, 11, 12, 15–17].
For example, Hsieh and Hsieh [8] examined the amounts of AFB1-DNA 
adducts in the 120 placenta tissue samples from women in Taipei, a high AFB1 
exposure area, and observed that 57.5% (69/120) of samples were positive AFB1-
DNA adducts with the range of 0.6 and 6.3 μmol/mol DNA. Furthermore, they 
found higher amount of AFB1-DNA adducts in samples collected in the summer 
than in the winter. Shirabe et al. [37] investigated the association between AFB1-
DNA adducts in hepatocyte nuclei and TP53 mutation in PHCC among Japanese 
population. They found that 6% (118/279) patients with PHCC and 16% (13/83) 
patients with HBV- and HCV-negative PHCC were positive for AFB1-DNA 
adducts. Higher hot-spot mutations in the TP53 gene were also found in these 
with positive AFB1-DNA adduct status [37]. A relatively large-size sample clini-
cal study, including 501 PHCC cases with different AFB1 exposure, also shows 
that positive status of AFB1-DNA adducts in the tumor tissues significantly 
increases the risk of TP53 mutations (OR = 3.38 and 95% CI = 2.23–5.11) [7]. 
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Following epidemiological studies on based clinical samples further prove that 
the amount of AFB1-DNA adducts is higher in the tumor tissues than in the peri-
tumor tissues [6]. This increasing tissular AFB1-DNA adducts are significantly 
associated with poor OS and RFS of patients with PHCC [6].
In this study, we designed and finished a hospital-based case-control study in 
the southwestern of Guangxi, a knowledge-high AFB1 exposure area. Our data 
exhibited that increasing the amount of AFB1-DNA adducts in peripheral white 
blood cells not only increased PHCC risk, but also modified the OS and RFS of 
patients with PHCC. Supporting our findings through several studies from high 
AFB1 exposure areas, the amount of blood AFB1-DNA adducts can reflect the 
levels of AFB1 exposure information and may be related to PHCC risk and prog-
nosis [11, 12, 14, 15, 17, 38]. Taken together, these results suggest that AFB1-DNA 
adducts in the blood as well as in the tumor tissues may be potential biomarkers for 
PHCC risk and outcome.
This study has several strengthens. We accomplished the predictive value 
analyses using these individuals only with AFB1 exposure but without HBV or 
HCV. This is done mainly because both HBV and HCV infection will alter effects of 
AFB1-DNA adducts predicting the risk and outcome of PHCC. Additionally, to con-
trol potential confounders such as age, gender, and race, the individually matched 
design was finished in this study. Therefore, our study may represent a relatively 
more actual predictive role of blood AFB1-DNA adducts.
To conclude, this study explored the association between blood AFB1-DNA 
adducts and the risk and prognosis of PHCC using a retrospective clinic-sample 
research approach and displayed that blood AFB1-DNA adduct may be a potential 
biomarker for HCC risk and outcome. Several limitations should be focused for our 
study. First, relatively small-size samples may underestimate the effects of blood 
AFB1-DNA adducts on PHCC risk and outcome. Second, selective bias may hap-
pen because of this hospital-based retrospective investigative design. Finally, the 
mechanical analyses for AFB1-DNA adducts predicting PHCC risk and prognosis 
were not finished. Thus, the blood AFB1-DNA adducts may be valuable biomark-
ers for predicting the risk and prognosis of PHCC once the present findings were 
proved by larger clinic samples and functional analyses.
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